Scabies: An ancient global disease with a need for new therapies

Jackson THOMAS, Gregory Peterson, Shelly Walton, Christine Carson, Mark NAUNTON, Kavya Baby

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Scabies is an ancient disease (documented as far back as 2500 years ago). It affects about 300 million people annually worldwide, and the prevalence is as high as about 60 % in Indigenous and Torres Strait Islander children in Australia. This is more than six times the rate seen in the rest of the developed world. Scabies is frequently complicated by bacterial infection leading to the development of skin sores and other more serious consequences such as septicaemia and chronic heart and kidney diseases. This causes a substantial social and economic burden especially in resource poor communities around the world. Discussion: Very few treatment options are currently available for the management of scabies infection. In this manuscript we briefly discuss the clinical consequences of scabies and the problems found (studies conducted in Australia) with the currently used topical and oral treatments. Current scabies treatment options are fairly ineffective in preventing treatment relapse, inflammatory skin reactions and associated bacterial skin infections. None have ovicidal, antibacterial, anti-inflammatory and/or anti-pruritic properties. Treatments which are currently available for scabies can be problematic with adverse effects and perhaps of greater concern the risk of treatment failure. The development of new chemical entities is doubtful in the near future. Though there may be potential for immunological control, the development of a vaccine or other immunotherapy modalities may be decades away. Summary: The emergence of resistance among scabies mites to classical scabicides and ineffectiveness of current treatments (in reducing inflammatory skin reactions and secondary bacterial infections associated with scabies), raise serious concerns regarding current therapy. Treatment adherence difficulties, and safety and efficacy uncertainties in the young and elderly, all signal the need to identify new treatments for scabies.
Original languageEnglish
Article number250
Pages (from-to)1-6
Number of pages6
JournalBMC Infectious Diseases
Volume15
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Scabies
Bacterial Infections
Skin
Therapeutics
Mites
Treatment Failure
Coinfection
Chronic Renal Insufficiency
Immunotherapy
Uncertainty
Heart Diseases
Sepsis
Anti-Inflammatory Agents
Vaccines
Economics
Safety
Recurrence

Cite this

THOMAS, Jackson ; Peterson, Gregory ; Walton, Shelly ; Carson, Christine ; NAUNTON, Mark ; Baby, Kavya. / Scabies: An ancient global disease with a need for new therapies. In: BMC Infectious Diseases. 2015 ; Vol. 15, No. 1. pp. 1-6.
@article{cc38210e642a458aa66794e4535a514a,
title = "Scabies: An ancient global disease with a need for new therapies",
abstract = "Background: Scabies is an ancient disease (documented as far back as 2500 years ago). It affects about 300 million people annually worldwide, and the prevalence is as high as about 60 {\%} in Indigenous and Torres Strait Islander children in Australia. This is more than six times the rate seen in the rest of the developed world. Scabies is frequently complicated by bacterial infection leading to the development of skin sores and other more serious consequences such as septicaemia and chronic heart and kidney diseases. This causes a substantial social and economic burden especially in resource poor communities around the world. Discussion: Very few treatment options are currently available for the management of scabies infection. In this manuscript we briefly discuss the clinical consequences of scabies and the problems found (studies conducted in Australia) with the currently used topical and oral treatments. Current scabies treatment options are fairly ineffective in preventing treatment relapse, inflammatory skin reactions and associated bacterial skin infections. None have ovicidal, antibacterial, anti-inflammatory and/or anti-pruritic properties. Treatments which are currently available for scabies can be problematic with adverse effects and perhaps of greater concern the risk of treatment failure. The development of new chemical entities is doubtful in the near future. Though there may be potential for immunological control, the development of a vaccine or other immunotherapy modalities may be decades away. Summary: The emergence of resistance among scabies mites to classical scabicides and ineffectiveness of current treatments (in reducing inflammatory skin reactions and secondary bacterial infections associated with scabies), raise serious concerns regarding current therapy. Treatment adherence difficulties, and safety and efficacy uncertainties in the young and elderly, all signal the need to identify new treatments for scabies.",
keywords = "Aboriginal, Benzyl peroxide, Indigenous, Ivermectin, MDA, Permethrin, Resistance, Scabies, Treatments",
author = "Jackson THOMAS and Gregory Peterson and Shelly Walton and Christine Carson and Mark NAUNTON and Kavya Baby",
year = "2015",
doi = "10.1186/s12879-015-0983-z",
language = "English",
volume = "15",
pages = "1--6",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",
number = "1",

}

Scabies: An ancient global disease with a need for new therapies. / THOMAS, Jackson; Peterson, Gregory; Walton, Shelly; Carson, Christine; NAUNTON, Mark; Baby, Kavya.

In: BMC Infectious Diseases, Vol. 15, No. 1, 250, 2015, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Scabies: An ancient global disease with a need for new therapies

AU - THOMAS, Jackson

AU - Peterson, Gregory

AU - Walton, Shelly

AU - Carson, Christine

AU - NAUNTON, Mark

AU - Baby, Kavya

PY - 2015

Y1 - 2015

N2 - Background: Scabies is an ancient disease (documented as far back as 2500 years ago). It affects about 300 million people annually worldwide, and the prevalence is as high as about 60 % in Indigenous and Torres Strait Islander children in Australia. This is more than six times the rate seen in the rest of the developed world. Scabies is frequently complicated by bacterial infection leading to the development of skin sores and other more serious consequences such as septicaemia and chronic heart and kidney diseases. This causes a substantial social and economic burden especially in resource poor communities around the world. Discussion: Very few treatment options are currently available for the management of scabies infection. In this manuscript we briefly discuss the clinical consequences of scabies and the problems found (studies conducted in Australia) with the currently used topical and oral treatments. Current scabies treatment options are fairly ineffective in preventing treatment relapse, inflammatory skin reactions and associated bacterial skin infections. None have ovicidal, antibacterial, anti-inflammatory and/or anti-pruritic properties. Treatments which are currently available for scabies can be problematic with adverse effects and perhaps of greater concern the risk of treatment failure. The development of new chemical entities is doubtful in the near future. Though there may be potential for immunological control, the development of a vaccine or other immunotherapy modalities may be decades away. Summary: The emergence of resistance among scabies mites to classical scabicides and ineffectiveness of current treatments (in reducing inflammatory skin reactions and secondary bacterial infections associated with scabies), raise serious concerns regarding current therapy. Treatment adherence difficulties, and safety and efficacy uncertainties in the young and elderly, all signal the need to identify new treatments for scabies.

AB - Background: Scabies is an ancient disease (documented as far back as 2500 years ago). It affects about 300 million people annually worldwide, and the prevalence is as high as about 60 % in Indigenous and Torres Strait Islander children in Australia. This is more than six times the rate seen in the rest of the developed world. Scabies is frequently complicated by bacterial infection leading to the development of skin sores and other more serious consequences such as septicaemia and chronic heart and kidney diseases. This causes a substantial social and economic burden especially in resource poor communities around the world. Discussion: Very few treatment options are currently available for the management of scabies infection. In this manuscript we briefly discuss the clinical consequences of scabies and the problems found (studies conducted in Australia) with the currently used topical and oral treatments. Current scabies treatment options are fairly ineffective in preventing treatment relapse, inflammatory skin reactions and associated bacterial skin infections. None have ovicidal, antibacterial, anti-inflammatory and/or anti-pruritic properties. Treatments which are currently available for scabies can be problematic with adverse effects and perhaps of greater concern the risk of treatment failure. The development of new chemical entities is doubtful in the near future. Though there may be potential for immunological control, the development of a vaccine or other immunotherapy modalities may be decades away. Summary: The emergence of resistance among scabies mites to classical scabicides and ineffectiveness of current treatments (in reducing inflammatory skin reactions and secondary bacterial infections associated with scabies), raise serious concerns regarding current therapy. Treatment adherence difficulties, and safety and efficacy uncertainties in the young and elderly, all signal the need to identify new treatments for scabies.

KW - Aboriginal

KW - Benzyl peroxide

KW - Indigenous

KW - Ivermectin

KW - MDA

KW - Permethrin

KW - Resistance

KW - Scabies

KW - Treatments

UR - http://www.scopus.com/inward/record.url?scp=84934294979&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/scabies-ancient-global-disease-need-new-therapies

U2 - 10.1186/s12879-015-0983-z

DO - 10.1186/s12879-015-0983-z

M3 - Article

VL - 15

SP - 1

EP - 6

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 250

ER -